Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothTransforming Drug Development with Science & Innovation.

            Contact the Supplier

            Lead Product(s): GP1681

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: CytoAgents

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 28, 2020

            Details:

            Partnership will focus on utilizing Quotient’s integrated service portfolio to support the rapid development of CytoAgents’ lead COVID-19 drug candidate, GP1681, for Phase I and II in 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): WP1122

            Therapeutic Area: Infections and Infectious Diseases Product Name: WP1122

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Moleculin Biotech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 15, 2020

            Details:

            Moleculin Biotech has signed an agreement with Sterling Pharma for US production of WP1122 to support its expanded development efforts in preparation for submitting a request to the US FDA for Investigational New Drug status for WP1122 for the potential treatment of COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TZLS-501

            Therapeutic Area: Infections and Infectious Diseases Product Name: TZLS-501

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: STC Biologics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 29, 2020

            Details:

            Tiziana's proprietary inhalation technology for direct delivery of mAbs or other small molecule drugs such as Remdesivir® (Roche) to lungs could potentially be a transformational therapy for developing a rapid treatment for COVID-19

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PolyPEPI-SCoV-2

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 15, 2020

            Details:

            Treos Bio has developed and successfully tested in silico a preventive COVID-19 peptide vaccine and has transferred all rights, including pending patent applications, to a newly formed subsidiary, PepTC Vaccines Limited.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Monoclonal antibodies

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: academia

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement June 09, 2020

            Details:

            AstraZeneca has licensed coronavirus-neutralising antibodies from Vanderbilt University, US, and plans to advance a pair of these mAbs into clinical development as a potential combination therapy for the prevention and treatment of COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Carbohydrate binding modules

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Thairm Bio

            Deal Size: $5.0 million Upfront Cash: Undisclosed

            Deal Type: Funding May 27, 2020

            Details:

            The funding is directed towards the clinical development of Neumifil, a first-in-class Carbohydrate Binding Modules (mCBMs), generated using the Company’s proprietary GlycoTarge™ platform, for the prevention and treatment of COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SARS-COV-2 Neutralising Affimers

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 15, 2020

            Details:

            Affimer reagents discovered that block the virus’ interaction with ACE2 which is key to how the virus infects human cells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Interferon Alpha 14

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 30, 2020

            Details:

            The company has patented a new Interferon-Alpha subtype called Interferon Alpha 14 which can be given to patients through injection or inhalation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Carbohydrate binding modules

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 28, 2020

            Details:

            Pneumagen's mCBMs were found to reduce the number of SARS-CoV-2 plaques when the mCBMs were used in both prevention and treatment of infection.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DNA vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 24, 2020

            Details:

            Scancell has developed DNA vaccines that target dendritic cells to stimulate high avidity T cells that survey and destroy diseased cells.

            PharmaCompass